Tumorigenicity as a clinical hurdle for pluripotent stem cell therapies (original) (raw)

• Ben-David, U. & Benvenisty, N. The tumorigenicity of human embryonic and induced pluripotent stem cells. Nat. Rev. Cancer 11, 268–277 (2011).
  Article CAS PubMed Google Scholar
• DeFrancesco, L. Fits and starts for Geron. Nat. Biotechnol. 27, 877 (2009).
  Article CAS Google Scholar
• Lee, A.S. et al. Effects of cell number on teratoma formation by human embryonic stem cells. Cell Cycle 8, 2608–2612 (2009).
  Article CAS PubMed Google Scholar
• Roy, N.S. et al. Functional engraftment of human ES cell–derived dopaminergic neurons enriched by coculture with telomerase-immortalized midbrain astrocytes. Nat. Med. 12, 1259–1268 (2006).
  Article CAS PubMed Google Scholar
• Kriks, S. et al. Dopamine neurons derived from human ES cells efficiently engraft in animal models of Parkinson's disease. Nature 480, 547–551 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Cui, L. et al. WNT signaling determines tumorigenicity and function of ESC-derived retinal progenitors. J. Clin. Invest. 123, 1647–1661 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Doi, D. et al. Prolonged maturation culture favors a reduction in the tumorigenicity and the dopaminergic function of human ESC-derived neural cells in a primate model of Parkinson's disease. Stem Cells 30, 935–945 (2012).
  Article CAS PubMed Google Scholar
• Amariglio, N. et al. Donor-derived brain tumor following neural stem cell transplantation in an ataxia telangiectasia patient. PLoS Med. 6, e1000029 (2009).
  Article PubMed PubMed Central CAS Google Scholar
• Cyranoski, D. Strange lesions after stem-cell therapy. Nature 465, 997 (2010).
  Article CAS PubMed Google Scholar
• Strauss, S. Geron trial resumes, but standards for stem cell trials remain elusive. Nat. Biotechnol. 28, 989–990 (2010).
  Article CAS PubMed Google Scholar
• Schwartz, S.D. et al. Embryonic stem cell trials for macular degeneration: a preliminary report. Lancet 379, 713–720 (2012).
  Article CAS PubMed Google Scholar
• Cyranoski, D. Stem cells cruise to clinic. Nature 494, 413 (2013).
  Article CAS PubMed Google Scholar
• Ben-Porath, I. et al. An embryonic stem cell–like gene expression signature in poorly differentiated aggressive human tumors. Nat. Genet. 40, 499–507 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Kim, J. et al. A Myc network accounts for similarities between embryonic stem and cancer cell transcription programs. Cell 143, 313–324 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Närvä, E. et al. High-resolution DNA analysis of human embryonic stem cell lines reveals culture-induced copy number changes and loss of heterozygosity. Nat. Biotechnol. 28, 371–377 (2010).
  Article PubMed CAS Google Scholar
• Meyer, N. & Penn, L.Z. Reflecting on 25 years with MYC. Nat. Rev. Cancer 8, 976–990 (2008).
  Article CAS PubMed Google Scholar
• Okita, K., Ichisaka, T. & Yamanaka, S. Generation of germline-competent induced pluripotent stem cells. Nature 448, 313–317 (2007).
  Article CAS PubMed Google Scholar
• Markoulaki, S. et al. Transgenic mice with defined combinations of drug-inducible reprogramming factors. Nat. Biotechnol. 27, 169–171 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Wernig, M., Meissner, A., Cassady, J.P. & Jaenisch, R. c-Myc is dispensable for direct reprogramming of mouse fibroblasts. Cell Stem Cell 2, 10–12 (2008).
  Article CAS PubMed Google Scholar
• Lin, C.Y. et al. Transcriptional amplification in tumor cells with elevated c-Myc. Cell 151, 56–67 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Hochedlinger, K., Yamada, Y., Beard, C. & Jaenisch, R. Ectopic expression of Oct-4 blocks progenitor-cell differentiation and causes dysplasia in epithelial tissues. Cell 121, 465–477 (2005).
  Article CAS PubMed Google Scholar
• Lee, T.K., Cheung, V.C. & Ng, I.O. Liver tumor-initiating cells as a therapeutic target for hepatocellular carcinoma. Cancer Lett. published online http://dx.doi.org/10.1016/j.canlet.2012.05.001 (28 May 2012).
• Bass, A.J. et al. SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat. Genet. 41, 1238–1242 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Rowland, B.D., Bernards, R. & Peeper, D.S. The KLF4 tumour suppressor is a transcriptional repressor of p53 that acts as a context-dependent oncogene. Nat. Cell Biol. 7, 1074–1082 (2005).
  Article CAS PubMed Google Scholar
• Mikkelsen, T.S. et al. Dissecting direct reprogramming through integrative genomic analysis. Nature 454, 49–55 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Soldner, F. et al. Parkinson's disease patient–derived induced pluripotent stem cells free of viral reprogramming factors. Cell 136, 964–977 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Woltjen, K. et al. piggyBac transposition reprograms fibroblasts to induced pluripotent stem cells. Nature 458, 766–770 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Stadtfeld, M., Nagaya, M., Utikal, J., Weir, G. & Hochedlinger, K. Induced pluripotent stem cells generated without viral integration. Science 322, 945–949 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Yu, J. et al. Human induced pluripotent stem cells free of vector and transgene sequences. Science 324, 797–801 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Jia, F. et al. A nonviral minicircle vector for deriving human iPS cells. Nat. Methods 7, 197–199 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Ban, H. et al. Efficient generation of transgene-free human induced pluripotent stem cells (iPSCs) by temperature-sensitive Sendai virus vectors. Proc. Natl. Acad. Sci. USA 108, 14234–14239 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Warren, L. et al. Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA. Cell Stem Cell 7, 618–630 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Lee, J. et al. Activation of innate immunity is required for efficient nuclear reprogramming. Cell 151, 547–558 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Miyoshi, N. et al. Reprogramming of mouse and human cells to pluripotency using mature microRNAs. Cell Stem Cell 8, 633–638 (2011).
  Article CAS PubMed Google Scholar
• Nakagawa, M., Takizawa, N., Narita, M., Ichisaka, T. & Yamanaka, S. Promotion of direct reprogramming by transformation-deficient Myc. Proc. Natl. Acad. Sci. USA 107, 14152–14157 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Desponts, C. & Ding, S. Using small molecules to improve generation of induced pluripotent stem cells from somatic cells. Methods Mol. Biol. 636, 207–218 (2010).
  Article CAS PubMed Google Scholar
• Laurent, L.C. et al. Dynamic changes in the copy number of pluripotency and cell proliferation genes in human ESCs and iPSCs during reprogramming and time in culture. Cell Stem Cell 8, 106–118 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Hussein, S.M. et al. Copy number variation and selection during reprogramming to pluripotency. Nature 471, 58–62 (2011).
  Article CAS PubMed Google Scholar
• Ohm, J.E. et al. Cancer-related epigenome changes associated with reprogramming to induced pluripotent stem cells. Cancer Res. 70, 7662–7673 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Harris, W.J. et al. The histone demethylase KDM1A sustains the oncogenic potential of MLL-AF9 leukemia stem cells. Cancer Cell 21, 473–487 (2012).
  Article CAS PubMed Google Scholar
• Gaudet, F. et al. Induction of tumors in mice by genomic hypomethylation. Science 300, 489–492 (2003).
  Article CAS PubMed Google Scholar
• Wollert, K.C. et al. Intracoronary autologous bone-marrow cell transfer after myocardial infarction: the BOOST randomised controlled clinical trial. Lancet 364, 141–148 (2004).
  Article PubMed Google Scholar
• Vanneste, E. et al. Chromosome instability is common in human cleavage-stage embryos. Nat. Med. 15, 577–583 (2009).
  Article CAS PubMed Google Scholar
• Hyka-Nouspikel, N. et al. Deficient DNA damage response and cell cycle checkpoints lead to accumulation of point mutations in human embryonic stem cells. Stem Cells 30, 1901–1910 (2012).
  Article CAS PubMed Google Scholar
• Desmarais, J.A. et al. Human embryonic stem cells fail to activate CHK1 and commit to apoptosis in response to DNA replication stress. Stem Cells 30, 1385–1393 (2012).
  Article CAS PubMed Google Scholar
• Mayshar, Y. et al. Identification and classification of chromosomal aberrations in human induced pluripotent stem cells. Cell Stem Cell 7, 521–531 (2010).
  Article CAS PubMed Google Scholar
• Draper, J.S. et al. Recurrent gain of chromosomes 17q and 12 in cultured human embryonic stem cells. Nat. Biotechnol. 22, 53–54 (2004).
  Article CAS PubMed Google Scholar
• Lefort, N. et al. Human embryonic stem cells reveal recurrent genomic instability at 20q11.21. Nat. Biotechnol. 26, 1364–1366 (2008).
  Article CAS PubMed Google Scholar
• Spits, C. et al. Recurrent chromosomal abnormalities in human embryonic stem cells. Nat. Biotechnol. 26, 1361–1363 (2008).
  Article CAS PubMed Google Scholar
• Amps, K. et al. Screening ethnically diverse human embryonic stem cells identifies a chromosome 20 minimal amplicon conferring growth advantage. Nat. Biotechnol. 29, 1132–1144 (2011).
  Article CAS PubMed Google Scholar
• Werbowetski-Ogilvie, T.E. et al. Characterization of human embryonic stem cells with features of neoplastic progression. Nat. Biotechnol. 27, 91–97 (2009).
  Article CAS PubMed Google Scholar
• Newman, A.M. & Cooper, J.B. Lab-specific gene expression signatures in pluripotent stem cells. Cell Stem Cell 7, 258–262 (2010).
  Article CAS PubMed Google Scholar
• Narsinh, K.H. et al. Single cell transcriptional profiling reveals heterogeneity of human induced pluripotent stem cells. J. Clin. Invest. 121, 1217–1221 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Pearl, J.I., Kean, L.S., Davis, M.M. & Wu, J.C. Pluripotent stem cells: immune to the immune system? Sci. Transl. Med. 4, 164ps125 (2012).
  Article CAS Google Scholar
• de Almeida, P.E., Ransohoff, J.D., Nahid, A. & Wu, J.C. Immunogenicity of pluripotent stem cells and their derivatives. Circ. Res. 112, 549–561 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Zhao, T., Zhang, Z.N., Rong, Z. & Xu, Y. Immunogenicity of induced pluripotent stem cells. Nature 474, 212–215 (2011).
  Article CAS PubMed Google Scholar
• Araki, R. et al. Negligible immunogenicity of terminally differentiated cells derived from induced pluripotent or embryonic stem cells. Nature 494, 100–104 (2013).
  Article CAS PubMed Google Scholar
• Guha, P., Morgan, J.W., Mostoslavsky, G., Rodrigues, N.P. & Boyd, A.S. Lack of immune response to differentiated cells derived from syngeneic induced pluripotent stem cells. Cell Stem Cell 12, 407–412 (2013).
  Article CAS PubMed Google Scholar
• Drukker, M. et al. Characterization of the expression of MHC proteins in human embryonic stem cells. Proc. Natl. Acad. Sci. USA 99, 9864–9869 (2002).
  Article CAS PubMed PubMed Central Google Scholar
• Rideout, W.M. III, Hochedlinger, K., Kyba, M., Daley, G.Q. & Jaenisch, R. Correction of a genetic defect by nuclear transplantation and combined cell and gene therapy. Cell 109, 17–27 (2002).
  Article CAS PubMed Google Scholar
• Pearl, J.I. et al. Short-term immunosuppression promotes engraftment of embryonic and induced pluripotent stem cells. Cell Stem Cell 8, 309–317 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Swijnenburg, R.J. et al. Immunosuppressive therapy mitigates immunological rejection of human embryonic stem cell xenografts. Proc. Natl. Acad. Sci. USA 105, 12991–12996 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Schwartz, S.D. et al. Embryonic stem cell trials for macular degeneration: a preliminary report. Lancet 379, 713–720 (2012).
  Article CAS PubMed Google Scholar
• Choo, A.B. et al. Selection against undifferentiated human embryonic stem cells by a cytotoxic antibody recognizing podocalyxin-like protein-1. Stem Cells 26, 1454–1463 (2008).
  Article CAS PubMed Google Scholar
• Tang, C. et al. An antibody against SSEA-5 glycan on human pluripotent stem cells enables removal of teratoma-forming cells. Nat. Biotechnol. 29, 829–834 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Dubois, N.C. et al. SIRPA is a specific cell-surface marker for isolating cardiomyocytes derived from human pluripotent stem cells. Nat. Biotechnol. 29, 1011–1018 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Ben-David, U. et al. Selective elimination of human pluripotent stem cells by an oleate synthesis inhibitor discovered in a high-throughput screen. Cell Stem Cell 12, 167–179 (2013).
  Article CAS PubMed Google Scholar
• Peckham, M.J., McElwain, T.J., Barrett, A. & Hendry, W.F. Combined management of malignant teratoma of the testis. Lancet 314, 267–270 (1979).
  Article Google Scholar
• Di Stasi, A. et al. Inducible apoptosis as a safety switch for adoptive cell therapy. N. Engl. J. Med. 365, 1673–1683 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Herszfeld, D. et al. CD30 is a survival factor and a biomarker for transformed human pluripotent stem cells. Nat. Biotechnol. 24, 351–357 (2006).
  Article CAS PubMed Google Scholar